Hodgkin lymphoma - clinical

Thierry Leblanc, Paul Harker-Murray, Christine Mauz-Körholz, Maurizio Mascarin, et al.

NIVOLUMAB AND BRENTUXIMAB VEDOTIN-BASED, RESPONSE-ADAPTED TREATMENT IN PRIMARY REFRACTORY AND IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN CHECKMATE 744

Conclusion: Response-adapted tx with nivolumab + BV achieved high CMR rates in primary refractory pts with cHL after 4 cycles of induction. In pediatric pts with a standard risk of relapse, induction with nivolumab + BV, followed by BV + bendamustine intensification for suboptimal response, demonstrated high CMR rates and a favorable safety profile prior to consolidation.

 

Andrea Gallamini, David Straus, Monika Dlugosz-Danecka, Sergey Alekseev, et al.

FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

Conclusion: Follow-up at 3 years demonstrates that frontline treatment of stage 3/4 cHL with A+AVD provides a durable treatment benefit compared with ABVD that is independent of PET2 status. While direct comparisons cannot be made, efficacy with A+AVD appears favorable in the context of findings with PET-adapted strategies, without requiring interim PET assessment, escalation of therapy, or bleomycin.

 

Eva Domingo-Domènech, Radhakrishnan Ramchandren, Antonio Rueda, Marek Trněný, et al.

NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR EXTENDED FOLLOW-UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY

Conclusion: With extended follow-up, nivolumab followed by N-AVD demonstrated a 21-month PFS rate of 83% per investigator, a high metabolic response rate with 75% CMR at EOT per IRC, with no new safety signals. Incorporation of Deauville assessment improved the concordance of CR between IRC- and investigator-assessed responses. Nivolumab followed by N-AVD provides a promising alternative treatment option in newly diagnosed advanced-stage cHL.

 

Michael Fuchs, Helen Goergen, Carsten Kobe, Hans Eich, et al.

PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY

Conclusion: In early-stage favorable HL, a positive PET after 2xABVD is associated with a larger tumor volume and represents a risk factor for PFS among patients treated with standard CMT, particularly when DS4 is considered as cutoff for positivity. PET-guided treatment intensification in this high-risk subgroup might help to reduce the frequency of relapses.

 

Hidde L.A. Posthuma, Josée M. Zijlstra, Otto Visser, Pieternella J. Lugtenburg, et al. 

PRIMARY THERAPY AND SURVIVAL AMONG ADULT PATIENTS WITH NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA (NLPHL): A POPULATION-BASED ANALYSIS IN THE NETHERLANDS, 1993-2016

Conclusion: In this large, nationwide population-based study, survival among various subgroups of patients with NLPHL during a 23-year period was largely comparable to the survival of the general population. Further, we noted no improved survival after the introduction of rituximab into the therapeutic arsenal of NLPHL since 2003. Future prospective studies in NLPHL are necessary to establish evidence-based treatment recommendations that consider the delicate balance between efficacy, toxicity, and quality of life.